EXEL Exelixis Inc
XNAS
64.58
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
EXEL
$64.58
—
Key stats
$64.58
- 52-Week Range
- $35.44 – $64.78
- YTD
- +48.19%
- IV Rank (30D)
- 47.36
- Straddle Price
- $5.85
- P/C Vol Ratio
- 0.40
- Market Cap
- $16.0B
- Open
- $64.12
- Day Range
- $64.11 – $64.78
- Volume
- 1,494,337
- Prev Close
- $64.39
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.81 |
| Cost of Equity (CAPM) | 9.18% (VRP-adj) |
| WACC | 9.20% |
| Volatility Risk Premium | +45.8pp (IV − HV30) |
| Effective Tax Rate | 16.9% |
| Rev. Growth (YoY, DCF input) | +5.2% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.05 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $1.2B |
| Return on Equity (TTM) | 46.7% |
| Book / Price | 10.5% |
| Gross Margin (TTM) | 96.5% |
| FCF Margin (TTM) | 48.1% |
| Debt / Equity | 0.00 |
| Quality Score | 5/6 — high quality (12y DCF) |
| Market-Implied Growth | +1.9% (reverse-DCF on current price) |
| SMA 50 | $57.46 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $59.97 |
| Bollinger Width / SMA20 | 23.7% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $18B |
Peers used for multiples: AMGN, GILD, HALO, LLY, MRNA, REGN, UTHR, VRTX
60-Day Conviction
67%
20-Day Fair Value
≈ by Nov 20, 2026
$65.48
α +1.4%
rank 31%
conviction
75%
40-Day Fair Value
≈ by Dec 21, 2026
$66.51
α +3.0%
rank 35%
conviction
84%
60-Day Fair Value
≈ by Jan 19, 2027
$65.93
α +2.1%
rank 26%
conviction
67%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $79.34 | 22% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $94.90 | 10% | median 28.4× · 6 peers |
| Peer EV/EBITDA | $76.51 | 10% | median 19.1× · 7 peers |
| Peer P/B | $104.11 | 2% | median 15.3× · 8 peers |
| Peer P/S | $75.44 | 7% | median 8.0× · 8 peers |
| Market Anchor (SMA50) | $57.46 | 28% | stability 64% (BB-width) |
| Options Expected (B-L 30d) | $66.14 | 22% | 21 strikes · skew +0.17 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $16.0B
- Employees
- 1,077
- List Date
- 2000-04-11
- CIK
- 0000939767
- Next Earnings
- 2026-10-29 (After-Close)
- EPS Forecast
- $0.79 (5 est.)
- Headquarters
- Alameda, CA
- Homepage
- https://www.exelixis.com
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 8.18% | -5.63% | 8.10% | -9.07% | -2.33% | -5.09% | -0.97% |
| Feb | -2.52% | 11.45% | -2.73% | 0.69% | 17.67% | 2.92% | 4.58% |
| Mar | 1.30% | 8.52% | 11.10% | 6.70% | -4.23% | 4.53% | 4.65% |
| Apr | 6.49% | -2.40% | -6.06% | -0.93% | 7.58% | 0.95% | 0.94% |
| May | -8.93% | -19.11% | 2.39% | -1.07% | 10.67% | 15.57% | -0.08% |
| Jun | -20.40% | 12.72% | -1.44% | 2.46% | 2.79% | 8.21% | 0.72% |
| Jul | -9.60% | -3.01% | 3.03% | 5.39% | -16.96% | -1.96% | -3.85% |
| Aug | 11.26% | -15.36% | 14.06% | 7.47% | 0.43% | -0.76% | 2.85% |
| Sep | 8.19% | -13.94% | -3.91% | 0.46% | 11.08% | 2.67% | 0.76% |
| Oct | -0.14% | 1.41% | -7.34% | 26.24% | -6.14% | 11.46%* | 4.25% |
| Nov | -22.63% | 1.67% | 3.76% | 6.86% | 16.05% | -- | 1.14% |
| Dec | 11.46% | -5.87% | 9.34% | -6.43% | 0.92% | -- | 1.88% |
| Total | -22.72% | -30.36% | 31.46% | 40.90% | 37.17% | 43.52% | 16.66% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $59.97
SMA 50: $57.46
SMA 200: $50.16
Current: $64.58
EMA 12: $61.65
EMA 26: $59.93
MACD: 1.7171 | Signal: 0.4830
BULLISH
ADX (14): 23.13
WEAK TREND
+DI: 36.23
−DI: 12.92
Momentum Oscillators
RSI (14): 74.63
OVERBOUGHT
Stoch %K: 95.28
Stoch %D: 91.01
Williams %R: -2.62
Volume & Volatility
BB Upper: $64.23
BB Lower: $55.71
OVERBOUGHT
OBV: 43,480,166
Vol SMA 20: 2,283,961
Vol ROC: -37.07%
ATR: $1.62
True Range: $0.67
HV 20: 18.7%
HV 30: 23.2%
HV 60: 34.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
This report provides an in-depth analysis of Exelixis, Inc. (EXEL) stock. Our overall assessment is NEUTRAL with a confidence level of 6 out of 10.
Key drivers include the company's strong financials, pipeline progress, and market trends. Primary risks are regulatory challenges and intense competition in the biotechnology industry.
Recent news sentiment has been generally positive, with headlines highlighting the growth potential of the metastatic prostate cancer market and the emergence of PARP inhibitors and PSMA-targeted radioligand therapies.
Technical Analysis
Trend Direction: Short-term: NEUTRAL (price action within a narrow range), Medium-term: BULLISH (SMA 50 and SMA 200 in an uptrend), Long-term: BEARISH (SMA 200 below SMA 20)
Support/Resistance Levels: Key price levels from moving averages are $56.78 (SMA 20) and $55.39 (SMA 50). The upper Bollinger Band is at $59.89, while the lower band is at $53.67.
Momentum Signals:
- RSI interpretation: Overbought (above 70)
- MACD signal: Bullish crossover above signal line
- Bollinger Bands position: Neutral
Volume Analysis: Volume trends suggest institutional interest with a volume rate of change of 144.83%. The On-Balance Volume (OBV) is positive, indicating buying pressure.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines highlight the growth potential of the metastatic prostate cancer market and the emergence of PARP inhibitors and PSMA-targeted radioligand therapies.
Sentiment Assessment: Aggregate news sentiment is POSITIVE with a score of 7 out of 10.
Catalyst Identification: The recent positive news headlines and the company's pipeline progress are potential catalysts for future price moves.
Market Narrative: The positive news narrative aligns with the technical signals, which indicate a neutral-to-bullish trend direction.
Risk & Volatility Assessment
Beta Interpretation: Low risk relative to market (beta < 0.8).
Volatility Regime: Current volatility is low compared to historical levels.
Options Market Signals:
- IV rank: Medium (30%)
- Put/call ratios: Bullish sentiment
- Unusual activity: None noted
Downside Protection: Support levels are at $56.78 and $55.39, with a stop-loss level of $54.50 to manage risk.
Market Context & Positioning
Sector Performance: The biotechnology sector is performing relatively well compared to the broader market.
Institutional Activity: Institutional interest is evident from the volume trends and OBV.
Correlation Analysis: EXEL's price movement is slightly correlated with the market (R-squared: 0.21).
Relative Valuation: EXEL is positioned within a trading range, with relative valuation compared to its peers and industry benchmarks.
Key Levels & Action Items
Critical Price Levels: Support/resistance levels are at $56.78, $55.39, and $59.89.
Breakout/Breakdown Levels: A breakout above $59.89 or a breakdown below $54.50 could trigger significant price moves.
Time-Sensitive Catalysts: No specific earnings dates or product launches were identified as catalysts for immediate action.
Risk Management: Stop-loss levels and position sizing considerations are essential to manage risk in this low-volatility environment.
By considering both technical and news signals, investors can make informed decisions about their investment positions in EXEL.
Generated
News
All EXEL news →
Earnings History
17 of 23 under expected move
Avg Expected Move
8.23%
Avg Actual Move
6.23%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | After-Close | 4.64% | 4.43% | 0.95x | Within |
| 2021-05-06 | After-Close | 8.18% | 8.14% | 1.00x | Within |
| 2021-08-05 | After-Close | 7.06% | 1.47% | 0.21x | Within |
| 2021-11-02 | After-Close | 8.82% | 12.07% | 1.37x | Exceeded |
| 2022-01-10 | After-Close | 7.39% | 0.00% | 0.00x | Within |
| 2022-05-10 | After-Close | 11.43% | 0.35% | 0.03x | Within |
| 2022-08-09 | After-Close | 9.50% | 7.41% | 0.78x | Within |
| 2022-11-01 | After-Close | 10.00% | 1.25% | 0.12x | Within |
| 2023-01-09 | After-Close | 5.46% | 1.90% | 0.35x | Within |
| 2023-05-09 | After-Close | 8.22% | 0.78% | 0.09x | Within |
| 2023-08-01 | After-Close | 5.50% | 3.62% | 0.66x | Within |
| 2023-11-01 | After-Close | 6.71% | 4.23% | 0.63x | Within |
| 2024-01-08 | After-Close | 6.88% | 3.24% | 0.47x | Within |
| 2024-04-30 | After-Close | 7.59% | 6.54% | 0.86x | Within |
| 2024-08-06 | After-Close | 13.01% | 13.09% | 1.01x | Exceeded |
| 2024-10-29 | After-Close | 7.31% | 12.91% | 1.77x | Exceeded |
| 2025-02-11 | After-Close | 8.46% | 0.03% | 0.00x | Within |
| 2025-05-13 | After-Close | 6.02% | 20.84% | 3.46x | Exceeded |
| 2025-07-28 | After-Close | 11.55% | 16.78% | 1.45x | Exceeded |
| 2025-11-04 | After-Close | 10.62% | 6.52% | 0.61x | Within |
| 2026-02-10 | After-Close | 8.43% | 0.09% | 0.01x | Within |
| 2026-05-05 | After-Close | 7.77% | 9.64% | 1.24x | Exceeded |
| 2026-08-05 | After-Close | 8.73% | 7.94% | 0.91x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
EXEL Options Activity & IV Rank
EXEL IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 39.6%
7-DTE IV: —
Expected Move: $5.85
7-DTE Move: $5.85
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 909
Put Volume: 361
P/C Volume: 0.397
BULLISH
Call OI: 5,936
Put OI: 3,140
P/C OI: 0.529
Total OI: 9,076
ATM Options Pricing
ATM Call: $3.25
ATM Put: $2.60
Call %: 5.0%
Put %: 4.0%
Chain Summary
Chain Volume: 6,030
Chain OI: 41,349
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 94th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
94%
vs own history
GEX tilt
+0.81
OI-weighted, today
Vanna tilt
-0.16
δ-sensitivity to IV
Charm tilt
-0.17
δ-decay vs time
? What is this?
· 23 ATM contracts, 12k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
30 DTE / 10d
49%
+7.2
pts
EXTREME
as of Oct 21 · ATM 39.3% / Wing 46.5%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)47.4MediumOct 21
Straddle Price (30 DTE)$5.85Oct 21
Beta Analysis
Risk Metrics
Beta: 0.6398
Alpha: 54.62%
Correlation: 0.2369
R-Squared: 5.6%
Stock Volatility: 34.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
EXEL Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 271,848,750 (as of 2026-07-03)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
15 filers$66.97M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $23.35M | 34.86% | 2026-06-30 |
| 2 | Millennium Management LLC Custodian | $12.04M | 17.97% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $8.86M | 13.24% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $3.87M | 5.78% | 2026-06-30 |
| 5 | Wolverine Trading, LLC Custodian | $3.80M | 5.68% | 2025-09-30 |
| 6 | Citadel Advisors LLC Custodian | $3.62M | 5.40% | 2026-06-30 |
| 7 | Twin Tree Management, LP | $3.51M | 5.24% | 2026-06-30 |
| 8 | Caption Management, LLC | $3.26M | 4.87% | 2026-06-30 |
| 9 | Jane Street Group, LLC Custodian | $1.95M | 2.92% | 2026-06-30 |
| 10 | Walleye Capital LLC | $1.32M | 1.97% | 2026-06-30 |
| 11 | Simplex Trading, LLC Custodian | $516.89K | 0.77% | 2026-06-30 |
| 12 | TUDOR INVESTMENT CORP ET AL | $418.96K | 0.63% | 2026-06-30 |
| 13 | CSS LLC/IL | $272.05K | 0.41% | 2026-06-30 |
| 14 | Raiffeisen Bank International AG | $163.23K | 0.24% | 2026-06-30 |
| 15 | Sonora Investment Management Group, LLC | $12.39K | 0.02% | 2025-09-30 |
12 filers$47.43M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $16.53M | 34.85% | 2026-06-30 |
| 2 | Sofinnova Investments, Inc. | $13.83M | 29.16% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $4.70M | 9.90% | 2026-06-30 |
| 4 | Caption Management, LLC | $3.26M | 6.88% | 2026-06-30 |
| 5 | IMC-Chicago, LLC Custodian | $2.83M | 5.96% | 2026-06-30 |
| 6 | Wolverine Trading, LLC Custodian | $2.38M | 5.01% | 2025-09-30 |
| 7 | Twin Tree Management, LP | $1.29M | 2.73% | 2026-06-30 |
| 8 | Jane Street Group, LLC Custodian | $979.38K | 2.06% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $843.36K | 1.78% | 2026-06-30 |
| 10 | Simplex Trading, LLC Custodian | $516.89K | 1.09% | 2026-06-30 |
| 11 | Walleye Capital LLC | $244.84K | 0.52% | 2026-06-30 |
| 12 | HAP TRADING, LLC | $27.62K | 0.06% | 2025-09-30 |
EXEL Insider Trading (Form 4)
Latest: 2026-08-12Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-12 | Mary C Beckerle | Director | Sell (S) | −9,812 | $53.66 | -$526.5K | EDGAR |
| 2026-06-03 | Sue Gail Eckhardt | Director | Sell (S) | −9,812 | $50.14 | -$492.0K | EDGAR |
| 2026-06-03 | Jack L Wyszomierski | Director | Sell (S) | −3,925 | $50.55 | -$198.4K | EDGAR |
| 2026-05-29 | David Edward Johnson | Director | Grant (A) | +38,266 opt | — | EDGAR | |
| 2026-05-29 | George Poste | Director | Award (A) | +8,367 | — | EDGAR | |
| 2026-05-29 | Jack L Wyszomierski | Director | Award (A) | +8,367 | — | EDGAR | |
| 2026-05-29 | Bob Oliver | Director | Award (A) | +8,367 | — | EDGAR | |
| 2026-05-29 | Mary C Beckerle | Director | Award (A) | +8,367 | — | EDGAR | |
| 2026-05-29 | Maria C Freire | Director | Award (A) | +8,367 | — | EDGAR | |
| 2026-05-29 | Julie Smith | Director | Award (A) | +8,367 | — | EDGAR | |
| 2026-05-29 | Sue Gail Eckhardt | Director | Award (A) | +8,367 | — | EDGAR | |
| 2026-05-29 | Tomas J. Heyman | Director | Award (A) | +8,367 | — | EDGAR | |
| 2026-05-29 | Stelios Papadopoulos | Director | Award (A) | +8,367 | — | EDGAR | |
| 2026-05-28 | Dana Aftab | EVP, Research and Development | Sell (S) | −43,451 | $50.35 | -$2.19M | EDGAR |
| 2026-05-22 | Patrick J. Haley | EVP, Commercial | Sell (S) | −32,110 | $49.81 | -$1.60M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
EXEL Insider Holdings
18 insiders · @ $64.58
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Michael Morrissey | President and CEO | 3,366,335 | $217.40M | -$58.10M | 126 | 2026-05-19 |
| 2 | David Edward Johnson | Director | 1,571,438 | $101.48M | $27.71M | 6 | 2026-05-29 |
| 3 | Stelios Papadopoulos | Director | 1,197,595 | $77.34M | -$15.23M | 38 | 2026-05-29 |
| 4 | Christopher J. Senner | EVP and CFO | 989,941 | $63.93M | -$24.02M | 57 | 2026-05-19 |
| 5 | Caligan Partners LP | Director | 928,906 | $59.99M | $0 | 2 | 2025-06-02 |
| 6 | Jeffrey Hessekiel | EVP & General Counsel | 719,395 | $46.46M | -$28.18M | 75 | 2025-05-16 |
| 7 | Dana Aftab | EVP, Research and Development | 600,576 | $38.79M | -$16.67M | 34 | 2026-05-28 |
| 8 | Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 538,169 | $34.75M | -$3.31M | 6 | 2025-05-16 |
| 9 | Patrick J. Haley | EVP, Commercial | 357,638 | $23.10M | -$35.85M | 93 | 2026-05-22 |
| 10 | Jack L Wyszomierski | Director | 284,384 | $18.37M | -$7.73M | 36 | 2026-06-03 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
EXEL Board & Officers
As of SEC filings through Aug 12, 2026Directors 12
- George Poste · on file since May 2006
- Jack L Wyszomierski · on file since May 2006
- Stelios Papadopoulos · on file since May 2006
- Michael Morrissey · listed since Sep 2011
- Julie Smith · since Sep 22, 2016
- Maria C Freire · since Apr 5, 2018
- Bob Oliver · since May 31, 2023
- Caligan Partners LP (entity) · since May 31, 2023
- David Edward Johnson · since May 31, 2023
- Tomas J. Heyman · since May 31, 2023
- Mary C Beckerle · since Jan 5, 2024
- Sue Gail Eckhardt · since Jan 5, 2024
Officers 6
- Michael Morrissey · President and CEO · listed since Aug 2010
- Christopher J. Senner · EVP and CFO · since Jul 15, 2015
- Brenda Hefti · SVP and General Counsel · since Nov 7, 2025
- Patrick J. Haley · EVP, Commercial · listed since Feb 2020
- Amy C. Peterson · EVP Prod Dev & Med Aff & CMO · since Aug 24, 2023
- Dana Aftab · EVP, Research and Development · listed since Oct 2025
Changes in the last 10 years (24)
| Nov 7, 2025 | Brenda Hefti became SVP and General Counsel |
| Nov 4, 2025 | The company announced the departure of Jeffrey Hessekiel as EVP & General Counsel in an SEC filing |
| Oct 10, 2025 | Dana Aftab listed as EVP, Research and Development (previously CSO/EVP Disc & Trans Research) in SEC filings |
| Sep 25, 2024 | Jeffrey Hessekiel listed as EVP & General Counsel (previously EVP, General Counsel & Sec) in SEC filings |
| Mar 27, 2024 | The company announced the departure of Jacqueline Wright from the board in an SEC filing |
| Jan 5, 2024 | Sue Gail Eckhardt became a director |
| Jan 5, 2024 | Mary C Beckerle became a director |
| Jan 2, 2024 | The company announced the departure of Alan M Garber from the board in an SEC filing |
| Aug 24, 2023 | Amy C. Peterson became EVP Prod Dev & Med Aff & CMO |
| May 31, 2023 | Tomas J. Heyman became a director |
| May 31, 2023 | David Edward Johnson became a director |
| May 31, 2023 | Caligan Partners LP became a director |
| May 31, 2023 | Bob Oliver became a director |
| May 7, 2023 | The company announced the departure of Lance Willsey from the board in an SEC filing |
| Apr 12, 2023 | The company announced the departure of Vincent T Marchesi from the board in an SEC filing |
| Apr 12, 2023 | The company announced the departure of Carl B Feldbaum from the board in an SEC filing |
| Dec 15, 2022 | Dana Aftab became CSO/EVP Disc & Trans Research |
| Apr 11, 2022 | The company announced the departure of Charles Cohen from the board in an SEC filing |
| Mar 8, 2022 | Jeffrey Hessekiel listed as EVP, General Counsel & Sec (previously EVP and General Counsel) in SEC filings |
| Jan 4, 2022 | Vicki L Goodman became EVP, Prod Dev & Med Aff &CMO |
| Dec 16, 2021 | Jacqueline Wright became a director |
| Feb 21, 2020 | Patrick J. Haley listed as EVP, Commercial (previously Sr. Vice President, Commercial) in SEC filings |
| Apr 5, 2018 | Maria C Freire became a director |
| Dec 19, 2016 | Patrick J. Haley became Sr. Vice President, Commercial |
Not reported recently (4)
- Vicki L Goodman · Last reported as EVP, Prod Dev & Med Aff &CMO in an SEC filing dated Apr 5, 2023
- Peter Lamb · Last reported as EVP, Scientific Strategy & CSO in an SEC filing dated Dec 16, 2022
- Gisela Schwab · Last reported as Pres, Prod Dev & Med Aff & CMO in an SEC filing dated Jul 28, 2021
- George A Scangos · Last reported as a director in an SEC filing dated May 20, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
EXEL Proposed Insider Sales (Form 144)
Latest: 2026-08-10
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $526K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
MARY BECKERLE (1, $526K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | MARY BECKERLE | Director | 9,812 | $526.5K | 2026-08-10 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-01 | Eckhardt Sue Gail | Director | 9,812 | $499.1K | 2026-06-01 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-06-01 | JACK L WYSZOMIERSKI | Director | 3,925 | $198.4K | 2026-06-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-26 | DANA T AFTAB | Officer | 43,451 | $2.19M | 2026-05-26 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-20 | PATRICK JOSEPH HALEY | Officer | 32,110 | $1.60M | 2026-05-20 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-18 | CHRISTOPHER J SENNER | Officer | 34,901 | $1.75M | 2026-05-18 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-18 | BRENDA JOY HEFTI | Officer | 6,625 | $332.6K | 2026-05-18 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-14 | BOMBORA RISE FOUNDATION | Family foundation of the CEO of EXEL. | 100,000 | $5.09M | 2026-05-14 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-07 | MARY BECKERLE | Director | 7,712 | $373.6K | 2026-05-07 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-07 | GEORGE H POSTE | Director | 60,000 | $2.74M | 2026-05-07 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-29
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-29 | 0000939767-26-000074 | EDGAR |
| 2026-05-05 | 0000939767-26-000058 | EDGAR |
| 2026-02-10 | 0000939767-26-000019 | EDGAR |
| 2026-01-12 | 0000939767-26-000003 | EDGAR |
| 2025-11-07 | 0000939767-25-000133 | EDGAR |
| 2025-11-04 | 0000939767-25-000127 | EDGAR |
| 2025-08-29 | 0000939767-25-000115 | EDGAR |
| 2025-07-28 | 0000939767-25-000111 | EDGAR |
| 2025-06-02 | 0000939767-25-000097 | EDGAR |
| 2025-05-13 | 0000939767-25-000074 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-10 | 0000939767-26-000021 | EDGAR |
| 2025-02-11 | 0000939767-25-000019 | EDGAR |
| 2024-02-06 | 0000939767-24-000028 | EDGAR |
| 2023-02-07 | 0000939767-23-000019 | EDGAR |
| 2022-02-18 | 0000939767-22-000026 | EDGAR |
| 2021-02-11 | 0001628280-21-001852 | EDGAR |
| 2020-02-25 | 0000939767-20-000035 | EDGAR |
| 2019-02-22 | 0000939767-19-000042 | EDGAR |
| 2018-02-26 | 0000939767-18-000023 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-05 | 0000939767-26-000059 | EDGAR |
| 2025-11-04 | 0000939767-25-000128 | EDGAR |
| 2025-07-28 | 0000939767-25-000113 | EDGAR |
| 2025-05-13 | 0000939767-25-000075 | EDGAR |
| 2024-10-29 | 0000939767-24-000150 | EDGAR |
| 2024-08-06 | 0000939767-24-000119 | EDGAR |
| 2024-04-30 | 0000939767-24-000058 | EDGAR |
| 2023-11-01 | 0000939767-23-000114 | EDGAR |
| 2023-08-01 | 0000939767-23-000079 | EDGAR |
| 2023-05-09 | 0000939767-23-000048 | EDGAR |
ETF Holders
221 ETFs hold EXEL
25 shown · $3.11B total exposure · 0.41% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJH iShares Core S&P Mid-Cap ETF | iShares (BlackRock) | 0.47% | $571.7M | $123.0B | 2026-10-20 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.02% | $437.1M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.17% | $309.5M | — | 2026-09-30 |
| 4 | XMHQ Invesco S&P MidCap Quality ETF | Invesco | 3.58% | $199.0M | — | 2026-10-20 |
| 5 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.39% | $172.1M | — | 2026-09-30 |
| 6 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.63% | $170.0M | $10.4B | 2026-10-20 |
| 7 | VXF Vanguard Extended Market ETF | Vanguard | 0.17% | $162.9M | — | 2026-09-30 |
| 8 | MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust | SPDR (State Street) | 0.46% | $119.6M | $25.8B | 2026-10-20 |
| 9 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 1.08% | $118.5M | $11.0B | 2026-10-20 |
| 10 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.50% | $104.8M | $3.0B | 2026-10-20 |
| 11 | IJK iShares S&P Mid-Cap 400 Growth ETF | iShares (BlackRock) | 0.92% | $96.0M | $10.5B | 2026-10-20 |
| 12 | SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF | SPDR (State Street) | 0.47% | $86.0M | $18.4B | 2026-10-20 |
| 13 | AVLV Avantis U.S. Large Cap Value ETF | Avantis | 0.34% | $76.0M | $22.3B | 2026-10-20 |
| 14 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.12% | $66.7M | $57.3B | 2026-10-20 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.07% | $58.2M | — | 2026-10-20 |
| 16 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.15% | $50.8M | — | 2026-10-20 |
| 17 | FMDE Fidelity Enhanced Mid Cap Core ETF | Fidelity | 0.54% | $46.1M | $8.5B | 2026-10-20 |
| 18 | VHT Vanguard Health Care ETF | Vanguard | 0.19% | $41.5M | — | 2026-09-30 |
| 19 | XOVR ERShares Private-Public Crossover ETF | Nport | 1.89% | $41.3M | — | 2026-06-30 |
| 20 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 1.07% | $36.9M | — | 2026-04-30 |
| 21 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.24% | $35.5M | — | 2026-05-31 |
| 22 | FTXH First Trust Nasdaq Pharmaceuticals ETF | First Trust | 2.49% | $28.3M | $1.1B | 2026-10-20 |
| 23 | COWG Pacer US Large Cap Cash Cows Growth Leaders ETF | Nport | 1.26% | $27.4M | — | 2026-04-30 |
| 24 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.03% | $26.6M | $84.5B | 2026-10-20 |
| 25 | MDYG State Street® SPDR® S&P 400™ Mid Cap Growth ETF | SPDR (State Street) | 0.92% | $25.8M | $2.8B | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
20.31
TTM Diluted EPS
$3.18
TTM Revenue
$2.44B
TTM Net Income
$860.62M
TTM Op. Cash Flow
$1.18B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-07-03 | $628.69M | $212.05M | $0.82 | $307.74M |
| Q1 '26 | 2026-04-03 | $610.81M | $210.47M | $0.79 | $251.84M |
| Q4 '25 | 2026-01-02 | $598.66M | $244.53M | $0.88 | $333.51M |
| Q3 '25 | 2025-10-03 | $597.75M | $193.58M | $0.69 | $290.32M |
| Q2 '25 | 2025-07-04 | $568.26M | $184.85M | $0.65 | $48.99M |
| Q1 '25 | 2025-04-04 | $555.45M | $159.62M | $0.55 | $211.44M |
| Q4 '24 | 2025-01-03 | $566.75M | $139.86M | $0.48 | $240.26M |
| Q3 '24 | 2024-09-27 | $539.54M | $117.97M | $0.40 | $271.34M |
| Q2 '24 | 2024-06-28 | $637.18M | $226.12M | $0.77 | $119.55M |
| Q1 '24 | 2024-03-29 | $425.23M | $37.32M | $0.12 | $68.82M |
| Q4 '23 | 2023-12-29 | $479.65M | $85.52M | $0.27 | $133.07M |
| Q3 '23 | 2023-09-29 | $471.92M | $1.04M | — | $-5.13M |
Q2 2026 • period ending 2026-07-03 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
20.31
P/B
9.52
P/S
7.21
EV/EBITDA
16.93
EV/Sales
7.09
ROE
46.7%
ROA
34.5%
Div Yield
0.00%
FCF Yield
6.74%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$17.56B
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
28.18M
SI % of Float
11.74%
Days to Cover
12.65
Short Vol Ratio
50.8%
Free Float
240.08M
Float %
96.9%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14